Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Endocrinology ; 149(8): 3850-9, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18420736

ABSTRACT

Ept1, Ept2, Ept6, and Ept9 are quantitative trait loci mapped in crosses between the ACI and Copenhagen (COP) rat strains as genetic determinants of responsiveness of the pituitary gland to estrogens. We have developed four congenic rat strains, each of which carries, on the genetic background of the ACI rat strain, alleles from the COP rat strain that span one of these quantitative trait loci. Relative to the female ACI rats, female ACI.COP-Ept1 rats exhibited reduced responsiveness to 17beta-estradiol (E2) in the pituitary gland, as evidenced by quantification of pituitary mass and circulating prolactin, and in the mammary gland, as evidenced by reduced susceptibility to E2-induced mammary cancer. The ACI.COP-Ept2 rat strain exhibited reduced responsiveness to E2 in the pituitary gland but did not differ from the ACI strain in regard to susceptibility to E2-induced mammary cancer. Interestingly, female Ept2 congenic rats exhibited increased responsiveness to E2 in the thymus, as evidenced by enhanced thymic atrophy. The ACI.COP-Ept6 rat strain exhibited increased responsiveness to E2 in the pituitary gland, which was associated with a qualitative phenotype suggestive of enhanced pituitary vascularization. The ACI.COP-Ept9 rat strain exhibited reduced responsiveness to E2 in the anterior pituitary gland, relative to the ACI rat strain. Neither Ept6 nor Ept9 impacted responsiveness to E2 in the mammary gland or thymus. These data indicate that each of these Ept genetic determinants of estrogen action is unique in regard to the tissues in which it exerts its effects and/or the direction of its effect on estrogen responsiveness.


Subject(s)
Drug Resistance/genetics , Estrogens/pharmacology , Pituitary Gland/drug effects , Quantitative Trait Loci/physiology , Animals , Animals, Congenic , Atrophy/genetics , Female , Genetic Markers/physiology , Genetic Predisposition to Disease , Incidence , Mammary Neoplasms, Animal/epidemiology , Mammary Neoplasms, Animal/genetics , Organ Size/drug effects , Organ Size/genetics , Organ Specificity/drug effects , Organ Specificity/genetics , Pituitary Gland/growth & development , Pituitary Gland/metabolism , Prolactin/blood , Rats , Thymus Gland/pathology
3.
Genetics ; 169(4): 2189-97, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15687265

ABSTRACT

Estrogens stimulate proliferation and enhance survival of the prolactin (PRL)-producing lactotroph of the anterior pituitary gland and induce development of PRL-producing pituitary tumors in certain inbred rat strains but not others. The goal of this study was to elucidate the genetic bases of estrogen-induced pituitary tumorigenesis in reciprocal intercrosses between the genetically related ACI and Copenhagen (COP) rat strains. Following 12 weeks of treatment with the synthetic estrogen diethylstilbestrol (DES), pituitary mass, an accurate surrogate marker of absolute lactotroph number, was increased 10.6-fold in ACI rats and 4.5-fold in COP rats. Composite interval mapping analyses of the phenotypically defined F(2) progeny from the reciprocal crosses identified six quantitative trait loci (QTL) that determine the pituitary growth response to DES. These loci reside on chromosome 6 [Estrogen-induced pituitary tumor (Ept)1], chromosome 3 (Ept2 and Ept6), chromosome 10 (Ept9), and chromosome 1 (Ept10 and Ept13). Together, these six Ept loci and one additional suggestive locus on chromosome 4 account for an estimated 40% of the phenotypic variance exhibited by the combined F(2) population, while 34% of the phenotypic variance was estimated to result from environmental factors. These data indicate that DES-induced pituitary mass behaves as a quantitative trait and provide information that will facilitate identification of genes that determine the tumorigenic response of the pituitary gland to estrogens.


Subject(s)
Estrogens/pharmacology , Pituitary Gland/drug effects , Pituitary Neoplasms/chemically induced , Pituitary Neoplasms/genetics , Animals , Biomarkers , Chromosome Mapping , Crosses, Genetic , Epistasis, Genetic , Estrogens/metabolism , Female , Gene Expression Regulation, Neoplastic , Genetic Markers , Genotype , Male , Models, Genetic , Models, Statistical , Organ Size , Phenotype , Pituitary Gland/pathology , Prolactin/metabolism , Quantitative Trait Loci , Rats , Sensitivity and Specificity , Sex Factors , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...